Drugs / attilizumab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07034326 Comparator | Jan 2025 → Dec 2028 expected | non-small cell lung carcinoma | Kong Fanming | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | attilizumab | “Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.” NCT07034326 ↗ |